Hardman & Co Research
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market
share
26-Sep-2019 / 07:30 GMT/BST
Hardman & Co Research: Continuing to gain market share
Allergy Therapeutics (AGY) is a long-established specialist in the prevention,
diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the
ultra-short course subcutaneous allergy immunotherapy (AIT), continues to gain
market share, despite its availability in the EU only on a "named-patient"
basis. Several products are in clinical development, with the aim of moving
the platform to full registration under the new regulatory frameworks in both
the EU and the US. Management has the plan and resources to achieve the
ultimate goal: to be the first to launch a fully-regulated subcutaneous
immunotherapy product in the US market.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/continuing-to-gain-ma
rket-share-2/ [1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link
To contact us: Contact:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street dmh@hardmanandco.com
London gp@hardmanandco.com
EC2M 1NH
Dr Dorothea
Hill
www.hardmanandco.com
Dr Gregoire
Pave
Follow us on Twitter
@HardmanandCo +44 20 7194
7622
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing
specialist research designed to improve investors' understanding of companies,
sectors, industries and investment securities. Our analysts are highly
experienced in their sectors, and have often been highly rated by professional
investors for their knowledge. Our focus is to raise companies' profiles
across the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been commissioned by
the company which is the subject of the note; this is clearly stated in the
disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative
of Capital Markets Strategy Ltd and is authorised and regulated by the
Financial Conduct Authority; our FCA registration number is 600843. Hardman
Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community,
market counterparties and sophisticated and high net worth investors as
defined in the rules of the regulatory bodies. It is not intended to be made
available to unsophisticated retail investors. Anyone who is unsure of their
categorisation should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security. Please read
the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
880133 26-Sep-2019
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a5c692663f7f1e6c2d25f7961719cb59&application_id=880133&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=880133&site_id=vwd&application_name=news
(END) Dow Jones Newswires
September 26, 2019 02:30 ET (06:30 GMT)
